CLSTN1

Across TCGA pan-cancer cohorts, CLSTN1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CLSTN1 data layer compared with 21 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CLSTN1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CLSTN1 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

HNSC, BLCA, and SKCM are the cancer types where CLSTN1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	IV	0.205	0.712	<.001	30	view →
BLCA	OS	Median	III,IV	0.051	0.684	<.001	21	view →
SKCM	OS	Median	IV	0.179	0.755	<.001	13	view →
SCLC	OS	Median	All	0.082	0.653	.002	6	view →
STAD	DFS	Median	II,III,IV	1.000	0.630	.030	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CLSTN1–HNSC (OS)

Open the HNSC breakdown →